NANIRX Therapeutics, Inc. (NANIRX)
 |
|
Website |
www.nanirx-pharma.com |
Sector Group |
Health Care and Sciences |
Fund Relationship |
NGN Capital |
Description |
In early-stage, pre-clinical bio-pharmaceutical company focused on developing technology to enhance the efficacy of existing monoclonal antibody drugs, as well as immuno-therapeutics targeted at treating breast cancer, Hepatitis C and other chronic infectious diseases. The company’s core technology is based on twenty-five years of research by Dr. David Cohen, who was co-chair of the Office of AIDS Research of the National Institutes of Health's HIV vaccine development committee, which in the mid-1990s had oversight over the development of worldwide HIV vaccine trials. NANIRX is currently headquartered in the Audubon Business & Technology Center (Columbia University’s incubator) in Washington Heights. |